Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (symbol: MCK) is a leading healthcare services and information technology company, dedicated to improving the business of healthcare globally. Ranked 11th on the Fortune 500 list, McKesson collaborates with a diverse range of stakeholders including payers, hospitals, physician offices, pharmacies, pharmaceutical companies, and other entities across the healthcare spectrum. The company's mission is to foster healthier organizations that deliver superior care to patients in every setting.
McKesson is one of the top three pharmaceutical wholesalers in the United States, engaging in the sourcing and distribution of branded, generic, and specialty pharmaceutical products. Their extensive client base includes retail chains, independent pharmacies, mail-order pharmacies, hospital networks, and healthcare providers. Alongside Cencora and Cardinal Health, McKesson commands over 90% of the US pharmaceutical wholesale industry.
Beyond the US, McKesson's reach extends to Canada, where they are involved in pharmaceutical wholesale and distribution. Additionally, McKesson supplies medical-surgical products and equipment to healthcare facilities and offers a range of technology solutions tailored for pharmacies.
McKesson's comprehensive service offerings include pharmaceutical and medical-surgical supply management, healthcare information technology solutions, and business and clinical services. The company is committed to helping its customers enhance their financial, operational, and clinical performance, ultimately aiming to deliver better patient care.
Recent achievements include strategic partnerships and innovative projects that continue to position McKesson as a key player in the healthcare industry. Their ongoing projects are designed to streamline operations and improve efficiency across the board, ensuring that healthcare providers can focus on patient care.
For more details on McKesson Corporation, visit www.mckesson.com.
McKesson (NYSE: MCK) has released its fiscal 2025 first quarter financial results, which are now available on the company's Investor Relations website. McKesson will host a live webcast of the earnings conference call for investors on Wednesday, August 7th at 4:30 PM ET to review these results. The audio webcast, earnings press release, financial tables, and slide presentation will be accessible on McKesson's Investor Relations website. This platform also provides information about upcoming events for the investor community.
McKesson (NYSE:MCK) has announced a 15% increase in its quarterly dividend to $0.71 per share, up from $0.62 in the previous quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. This marks McKesson's eighth consecutive annual dividend increase, reflecting the company's confidence in its business fundamentals and financial strength. CEO Brian Tyler emphasized McKesson's commitment to a disciplined capital deployment strategy, focusing on growth and shareholder value creation. The dividend hike underscores the company's strong balance sheet and robust free cash flow generation capabilities.
McKesson (NYSE: MCK) is set to release its first quarter fiscal 2025 financial results on August 7, 2024, after market close. A live webcast of the earnings conference call will be held at 4:30 PM Eastern Time, available on McKesson’s Investor Relations website. The webcast will cover financial results, including earnings release, financial tables, and a slide presentation.
McKesson announced the election of Dr. Deborah Dunsire to its board of directors, effective June 3, 2024. Dr. Dunsire, with over 30 years of experience in the biopharmaceutical and oncology sectors, will also serve on the Compensation and Talent Committee and Finance Committee. She recently retired as CEO of H. Lundbeck A/S and has held leadership roles at XTuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium: The Takeda Oncology Company.
Meanwhile, current board members Linda Mantia and Susan Salka will not stand for re-election at the 2024 Annual Meeting of Shareholders. The board size will reduce to 11 members, 10 of whom will be independent. McKesson's board chair, Donald Knauss, expressed gratitude for their contributions.
McKesson (NYSE: MCK) has reported its fiscal 2024 fourth quarter financial results. The earnings conference call for investors will be held today, May 7th. The company's financial results, along with a slide presentation, can be accessed on McKesson's Investor Relations website.